Such findings, together with similar ones in other cancers, promoted the development of phase I and II clinical trials, using CXCR1 and CXCR2 inhibitors in combination with anti-PD-1 in patients with metastatic CRC with MSI-L and Ras-mutation (195). This evidence concerns the gene PDCD1 and cancer.